$9.18
1.44% today
Nasdaq, Sep 19, 05:48 pm CET
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Ocular Therapeutix Inc Stock price

$9.05
+0.32 3.67% 1M
-0.39 4.13% 6M
+4.59 102.91% YTD
+5.73 172.59% 1Y
-0.97 9.68% 3Y
+4.75 110.47% 5Y
-6.69 42.50% 10Y
Nasdaq, Closing price Wed, Sep 18 2024
+0.29 3.31%
ISIN
US67576A1007
Symbol
OCUL
Sector
Industry

Key metrics

Market capitalization $1.41b
Enterprise Value $1.03b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 16.80
P/S ratio (TTM) P/S ratio 23.09
P/B ratio (TTM) P/B ratio 3.73
Revenue growth (TTM) Revenue growth 11.90%
Revenue (TTM) Revenue $61.10m
EBIT (operating result TTM) EBIT $-114.47m
Free Cash Flow (TTM) Free Cash Flow $-90.59m
Cash position $459.69m
EPS (TTM) EPS $-1.35
P/E forward negative
P/S forward 21.32
EV/Sales forward 15.51
Short interest 11.82%
Show more

Is Ocular Therapeutix Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.

Ocular Therapeutix Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Ocular Therapeutix Inc forecast:

8x Buy
100%

Analyst Opinions

8 Analysts have issued a Ocular Therapeutix Inc forecast:

Buy
100%

Financial data from Ocular Therapeutix Inc

Assets
Jun '24
499 499
Cash 460 460
Claims 30 30
Inventories 2.55 2.55
Other current assets Other current assets Current assets 6.12 6.12
19 19
Property, plant and equipment 17 17
Financial assets 1.61 1.61
Intangible Assets - -
Other fixed assets Other assets Fixed assets - -
Total Assets 517 517
Liabilities
Jun '24
Equity 378 378
139 139
Current liabilities 30 30
Non-current liabilities 109 109
Total Capital 517 517

In millions USD.

Don't miss a Thing! We will send you all news about Ocular Therapeutix Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Ocular Therapeutix Inc Stock News

Neutral
GlobeNewsWire
14 days ago
BEDFORD, Mass., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced multiple presentations across four retina meetings being held in Portugal and Spain in...
Neutral
GlobeNewsWire
15 days ago
BEDFORD, Mass., Sept. 04, 2024 (GLOBE NEWSWIRE) -- Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to improving vision in the real world through the development and commercialization of innovative therapies for retinal diseases and other eye conditions, today announced that it will participate in two investor conferences in September:
Neutral
Seeking Alpha
about one month ago
Ocular Therapeutix, Inc. (NASDAQ:OCUL ) Q2 2024 Earnings Conference Call August 7, 2024 8:00 AM ET Company Participants Bill Slattery - VP, IR Pravin Dugel - Executive Chairman, President, CEO Conference Call Participants Tazeen Ahmad - Bank of America Merrill Lynch Biren Amin - Piper Sandler Tara Bancroft - TD Cowen Colleen Kusy - Baird Kelly Shi - Jefferies Sean McCutcheon - Raymond James Yi ...
More Ocular Therapeutix Inc News

Company Profile

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Head office United States
CEO Pravin Dugel
Employees 267
Founded 2006
Website www.ocutx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today